Clinical Trial Update: Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population [Phase 4]

View source ↗

Summary

Phase 4 study evaluating de novo everolimus for kidney transplant recipients with delayed graft function.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Graft Function Following Renal Transplantation

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: MARIO ABBUD FILHO | Conditions: Delayed Function of Renal Transplant | Phase 4 | Status: UNKNOWN